Vical (NAS: VICL) reported earnings on Feb. 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Vical missed estimates on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped significantly, and GAAP loss per share stayed the same.
Margins dropped across the board.
Vical tallied revenue of $1.9 million. The five analysts polled by S&P Capital IQ predicted revenue of $2.0 million. GAAP sales were 34% lower than the prior-year quarter's $2.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.09. The four earnings estimates compiled by S&P Capital IQ anticipated -$0.12 per share. GAAP EPS of -$0.09 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was -33.0%, 3,380 basis points worse than the prior-year quarter. Operating margin was -364.7%, 12,040 basis points worse than the prior-year quarter. Net margin was -342.3%, 11,050 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $3.5 million. On the bottom line, the average EPS estimate is -$0.11.
Next year's average estimate for revenue is $16.6 million. The average EPS estimate is -$0.39.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 154 members rating the stock outperform and 11 members rating it underperform. Among 39 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 35 give Vical a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Vical is outperform, with an average price target of $6.75.
The biotechnology and healthcare investing landscape is littered with also-rans and a few major winners. Is Vical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
Add Vical to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.